S&P 500   3,762.34 (-2.27%)
DOW   30,377.73 (-1.81%)
QQQ   322.01 (-2.00%)
AAPL   143.02 (-0.10%)
MSFT   234.47 (+0.92%)
FB   274.80 (-2.57%)
GOOGL   1,826.63 (-4.26%)
AMZN   3,260.40 (-1.98%)
TSLA   877.68 (-0.61%)
NVDA   518.66 (-3.49%)
BABA   262.54 (-1.27%)
CGC   38.23 (+7.63%)
GE   10.80 (-4.34%)
MU   76.15 (-4.23%)
AMD   89.94 (-5.04%)
NIO   57.69 (-4.34%)
T   29.10 (-2.18%)
F   10.81 (-3.40%)
ACB   11.47 (+7.50%)
BA   193.65 (-4.16%)
DIS   163.30 (-3.69%)
NFLX   533.60 (-5.04%)
GILD   65.59 (-1.66%)
S&P 500   3,762.34 (-2.27%)
DOW   30,377.73 (-1.81%)
QQQ   322.01 (-2.00%)
AAPL   143.02 (-0.10%)
MSFT   234.47 (+0.92%)
FB   274.80 (-2.57%)
GOOGL   1,826.63 (-4.26%)
AMZN   3,260.40 (-1.98%)
TSLA   877.68 (-0.61%)
NVDA   518.66 (-3.49%)
BABA   262.54 (-1.27%)
CGC   38.23 (+7.63%)
GE   10.80 (-4.34%)
MU   76.15 (-4.23%)
AMD   89.94 (-5.04%)
NIO   57.69 (-4.34%)
T   29.10 (-2.18%)
F   10.81 (-3.40%)
ACB   11.47 (+7.50%)
BA   193.65 (-4.16%)
DIS   163.30 (-3.69%)
NFLX   533.60 (-5.04%)
GILD   65.59 (-1.66%)
S&P 500   3,762.34 (-2.27%)
DOW   30,377.73 (-1.81%)
QQQ   322.01 (-2.00%)
AAPL   143.02 (-0.10%)
MSFT   234.47 (+0.92%)
FB   274.80 (-2.57%)
GOOGL   1,826.63 (-4.26%)
AMZN   3,260.40 (-1.98%)
TSLA   877.68 (-0.61%)
NVDA   518.66 (-3.49%)
BABA   262.54 (-1.27%)
CGC   38.23 (+7.63%)
GE   10.80 (-4.34%)
MU   76.15 (-4.23%)
AMD   89.94 (-5.04%)
NIO   57.69 (-4.34%)
T   29.10 (-2.18%)
F   10.81 (-3.40%)
ACB   11.47 (+7.50%)
BA   193.65 (-4.16%)
DIS   163.30 (-3.69%)
NFLX   533.60 (-5.04%)
GILD   65.59 (-1.66%)
S&P 500   3,762.34 (-2.27%)
DOW   30,377.73 (-1.81%)
QQQ   322.01 (-2.00%)
AAPL   143.02 (-0.10%)
MSFT   234.47 (+0.92%)
FB   274.80 (-2.57%)
GOOGL   1,826.63 (-4.26%)
AMZN   3,260.40 (-1.98%)
TSLA   877.68 (-0.61%)
NVDA   518.66 (-3.49%)
BABA   262.54 (-1.27%)
CGC   38.23 (+7.63%)
GE   10.80 (-4.34%)
MU   76.15 (-4.23%)
AMD   89.94 (-5.04%)
NIO   57.69 (-4.34%)
T   29.10 (-2.18%)
F   10.81 (-3.40%)
ACB   11.47 (+7.50%)
BA   193.65 (-4.16%)
DIS   163.30 (-3.69%)
NFLX   533.60 (-5.04%)
GILD   65.59 (-1.66%)
Log in
NASDAQ:GH

Guardant Health Stock Forecast, Price & News

$150.13
+0.22 (+0.15 %)
(As of 01/27/2021 02:33 PM ET)
Add
Compare
Today's Range
$142.16
Now: $150.13
$151.97
50-Day Range
$121.62
MA: $139.01
$163.34
52-Week Range
$55.90
Now: $150.13
$168.52
Volume19,367 shs
Average Volume1.24 million shs
Market Capitalization$15.01 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.57
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors. In addition, the company is developing LUNAR-2 for early detection of cancer in higher risk individuals. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. The company has collaboration agreement with Radius Health, Inc. to develop liquid biopsy companion diagnostic for elacestrant. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.

MarketRank

Overall MarketRank

1.50 out of 5 stars

Medical Sector

422nd out of 1,925 stocks

Medical Laboratories Industry

7th out of 39 stocks

Analyst Opinion: 2.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone855-698-8887
Employees622
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$214.38 million
Book Value$8.50 per share

Profitability

Net Income$-75,650,000.00

Miscellaneous

Market Cap$15.01 billion
Next Earnings Date2/22/2021 (Estimated)
OptionableNot Optionable
$150.13
+0.22 (+0.15 %)
(As of 01/27/2021 02:33 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GH News and Ratings via Email

Sign-up to receive the latest news and ratings for GH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Guardant Health (NASDAQ:GH) Frequently Asked Questions

How has Guardant Health's stock been impacted by Coronavirus (COVID-19)?

Guardant Health's stock was trading at $62.95 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GH stock has increased by 140.7% and is now trading at $151.53.
View which stocks have been most impacted by COVID-19
.

Is Guardant Health a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Guardant Health stock.
View analyst ratings for Guardant Health
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Guardant Health?

Wall Street analysts have given Guardant Health a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Guardant Health wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Helmy Eltoukhy's approval rating as Guardant Health's CEO?

52 employees have rated Guardant Health CEO Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among Guardant Health's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

When is Guardant Health's next earnings date?

Guardant Health is scheduled to release its next quarterly earnings announcement on Monday, February 22nd 2021.
View our earnings forecast for Guardant Health
.

How were Guardant Health's earnings last quarter?

Guardant Health, Inc. (NASDAQ:GH) posted its quarterly earnings results on Thursday, November, 5th. The company reported ($0.78) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.34) by $0.44. The company earned $74.66 million during the quarter, compared to analysts' expectations of $65.99 million. Guardant Health had a negative net margin of 67.14% and a negative trailing twelve-month return on equity of 19.22%. The firm's revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.14) earnings per share.
View Guardant Health's earnings history
.

What price target have analysts set for GH?

9 brokerages have issued 12 month price targets for Guardant Health's shares. Their forecasts range from $103.00 to $190.00. On average, they anticipate Guardant Health's stock price to reach $146.80 in the next twelve months. This suggests that the stock has a possible downside of 3.1%.
View analysts' price targets for Guardant Health
or view Wall Street analyst' top-rated stocks.

Who are some of Guardant Health's key competitors?

What other stocks do shareholders of Guardant Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), The Trade Desk (TTD), Square (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).

Who are Guardant Health's key executives?

Guardant Health's management team includes the following people:
  • Mr. AmirAli Talasaz, Pres, COO & Chairman (Age 41, Pay $914.91k)
  • Dr. Helmy Eltoukhy Ph.D., Co-Founder, CEO & Director (Age 42, Pay $914.91k)
  • Dr. Richard B. Lanman, Advisor (Age 66, Pay $540.15k)
  • Mr. Michael Bell, Chief Financial Officer (Age 52)
  • Mr. Kumud Kalia, Chief Information Officer
  • Mr. John G. Saia, Sr. VP, Gen. Counsel & Corp. Sec. (Age 48)
  • Ms. Amelia Merrill, VP of People
  • Mr. Mark Jacobstein, Chief User Engagement Officer
  • Mr. Andy Ament, Sr. VP of Operations
  • Mr. Daniel Simon, Sr. VP of Biopharma Bus. Devel.

When did Guardant Health IPO?

(GH) raised $200 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

What is Guardant Health's stock symbol?

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Who are Guardant Health's major shareholders?

Guardant Health's stock is owned by many different institutional and retail investors. Top institutional investors include Ardevora Asset Management LLP (0.47%), Frontier Capital Management Co. LLC (0.29%), Westwood Management Corp IL (0.29%), Chicago Capital LLC (0.25%), Rhenman & Partners Asset Management AB (0.17%) and Candriam Luxembourg S.C.A. (0.09%). Company insiders that own Guardant Health stock include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Samir Kaul, Stanley J Meresman, Timothy P Eckersley and Vision Fund (Aiv M1) Softbank.
View institutional ownership trends for Guardant Health
.

Which major investors are selling Guardant Health stock?

GH stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Rhenman & Partners Asset Management AB, Candriam Luxembourg S.C.A., and Chicago Capital LLC. Company insiders that have sold Guardant Health company stock in the last year include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Samir Kaul, and Stanley J Meresman.
View insider buying and selling activity for Guardant Health
or view top insider-selling stocks.

Which major investors are buying Guardant Health stock?

GH stock was bought by a variety of institutional investors in the last quarter, including Ardevora Asset Management LLP, Janney Montgomery Scott LLC, Caliber Wealth Management LLC, Westwood Management Corp IL, Nisa Investment Advisors LLC, Exane Derivatives, Strs Ohio, and Sowell Financial Services LLC.
View insider buying and selling activity for Guardant Health
or or view top insider-buying stocks.

How do I buy shares of Guardant Health?

Shares of GH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Guardant Health's stock price today?

One share of GH stock can currently be purchased for approximately $151.53.

How big of a company is Guardant Health?

Guardant Health has a market capitalization of $15.15 billion and generates $214.38 million in revenue each year. The company earns $-75,650,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Guardant Health employs 622 workers across the globe.

What is Guardant Health's official website?

The official website for Guardant Health is www.guardanthealth.com.

How can I contact Guardant Health?

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The company can be reached via phone at 855-698-8887.

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.